Clinical Trials Sponsored by Cancer Prevention Pharmaceuticals, Inc

Total 456 results

Cancer Prevention Pharmaceuticals, Inc.

Completed

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis

United States, Belgium, Germany, Canada, Netherlands, Spain, United Kingdom
Cancer Prevention Pharmaceuticals, Inc.

Withdrawn

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc.
University of Arizona

Withdrawn

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.

Active, not recruiting

Chemoprevention of Gastric Carcinogenesis

Gastric Cancer | Gastric Intestinal Metaplasia

Honduras, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.

Active, not recruiting

S0820, Adenoma and Second Primary Prevention Trial (PACES)

Colorectal Neoplasms

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc; Colorado Prevention Center

Completed

An Observational Study of the Functional Capacity of Heart Failure

Acute Heart Failure

United States
UNC Lineberger Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Diffuse Large B-cell Lymphoma

United States
Colorado Prevention Center
Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluation of Cilostazol in Combination With L-Carnitine (ECLECTIC)

Peripheral Arterial Disease | Intermittent Claudication | Peripheral Vascular Disease

United States
ARCA Biopharma, Inc.
Colorado Prevention Center

Completed

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN)

Covid19

United States, Argentina, Brazil
Emily K. Sims
Juvenile Diabetes Research Foundation; Cancer Prevention Pharmaceuticals, Inc.

Recruiting

TArgeting Type 1 Diabetes Using POLyamines (TADPOL) (TADPOL)

Type 1 Diabetes

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.; Syndax Pharmaceuticals

Recruiting

A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Recruiting

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
AVEO Pharmaceuticals, Inc.

Recruiting

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Recruiting

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Myelodysplastic Syndromes | AML, Adult | ALL, Adult | CLL, Refractory | CML, Refractory

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
M.D. Anderson Cancer Center
Syros Pharmaceuticals Inc.

Withdrawn

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

Advanced Cancers

United States
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Brain and Central Nervous System Tumors

United States
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Unknown

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Leukemia

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Acupuncture for Chemo-Induced Peripheral Neuropathy

Lymphoma | Peripheral Neuropathy | Myeloma

United States
M.D. Anderson Cancer Center
Enzon Pharmaceuticals, Inc.

Completed

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

Invasive Fungal Infections | Hematologic Malignancies

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Lymphoma | Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Not yet recruiting

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

United States
Ionis Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Completed

A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors

Advanced Solid Tumors

United States
M.D. Anderson Cancer Center
Spectrum Pharmaceuticals, Inc

Completed

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Leukemia

United States
M.D. Anderson Cancer Center
Pacira Pharmaceuticals, Inc

Terminated

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

Gynecologic Cancer | Malignant Neoplasms of Female Genital Organs

United States
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

Lymphoma, B-Cell

United States
M.D. Anderson Cancer Center
Spectrum Pharmaceuticals, Inc

Withdrawn

A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Lymphoma
M.D. Anderson Cancer Center
Infinity Pharmaceuticals, Inc.

Withdrawn

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Leukemia
M.D. Anderson Cancer Center
Concordia Pharmaceuticals, Inc

Completed

FTS Study in Patients With Advanced Hematologic Malignancies

Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Astex Pharmaceuticals, Inc.

Recruiting

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Solid Tumor | Urethral Cancer

United States
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Completed

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

AML | MDS

United States
Jonsson Comprehensive Cancer Center
Progenics Pharmaceuticals, Inc.

Terminated

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)

Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Lung Cancer | Mesothelioma

United States
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Spectrum Pharmaceuticals, Inc

Completed

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Lymphoma | Leukemia

United States
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Withdrawn

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Malignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital Organs
M.D. Anderson Cancer Center
Reata Pharmaceuticals, Inc.

Terminated

RTA 744 Injection in Patients With Leptomeningeal Disease

Lymphoma | Leukemia | Solid Tumor | Brain Tumor | Neoplastic Meningitis

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Completed

Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Access Pharmaceuticals, Inc.

Completed

4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies

Leukemia

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
M.D. Anderson Cancer Center
Reata Pharmaceuticals, Inc.

Completed

RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies

Solid Tumors | Lymphoid Malignancies

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

Lymphoma | Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
Enzon Pharmaceuticals, Inc.

Completed

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Acute Lymphoblastic Leukemia

United States

Clinical Trials Sponsored by Cancer Prevention Pharmaceuticals, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations